275 related articles for article (PubMed ID: 24374682)
1. PIK3CA activating mutations in facial infiltrating lipomatosis.
Maclellan RA; Luks VL; Vivero MP; Mulliken JB; Zurakowski D; Padwa BL; Warman ML; Greene AK; Kurek KC
Plast Reconstr Surg; 2014 Jan; 133(1):12e-19e. PubMed ID: 24374682
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth.
Blackburn PR; Milosevic D; Marek T; Folpe AL; Howe BM; Spinner RJ; Carter JM
Mod Pathol; 2020 Mar; 33(3):420-430. PubMed ID: 31481664
[TBL] [Abstract][Full Text] [Related]
3. Somatic mosaicism for the p.His1047Arg mutation in PIK3CA in a girl with mesenteric lipomatosis.
Cohen AS; Townsend KN; Xiang QS; Attariwala R; Borchers C; Senger C; Picker W; Levi J; Yewchuk L; Tan J; Eydoux P; Lum A; Yong SL; McKinnon ML; Lear SA; Everett R; Jones SJ; Yip S; Gibson WT
Am J Med Genet A; 2014 Sep; 164A(9):2360-4. PubMed ID: 24903541
[TBL] [Abstract][Full Text] [Related]
4. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA.
Luks VL; Kamitaki N; Vivero MP; Uller W; Rab R; Bovée JV; Rialon KL; Guevara CJ; Alomari AI; Greene AK; Fishman SJ; Kozakewich HP; Maclellan RA; Mulliken JB; Rahbar R; Spencer SA; Trenor CC; Upton J; Zurakowski D; Perkins JA; Kirsh A; Bennett JT; Dobyns WB; Kurek KC; Warman ML; McCarroll SA; Murillo R
J Pediatr; 2015 Apr; 166(4):1048-54.e1-5. PubMed ID: 25681199
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
[TBL] [Abstract][Full Text] [Related]
6. [PIK3CA-related overgrowth syndrome (PROS)].
Venot Q; Canaud G
Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
[TBL] [Abstract][Full Text] [Related]
7. Delineation of the phenotypes and genotypes of facial infiltrating lipomatosis associated with PIK3CA mutations.
Chen H; Sun B; Gao W; Qiu Y; Hua C; Lin X
Orphanet J Rare Dis; 2023 Jul; 18(1):189. PubMed ID: 37452404
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
[TBL] [Abstract][Full Text] [Related]
9. Congenital infiltrating lipomatosis of the face with lingual mucosal neuromas associated with a PIK3CA mutation.
Briand C; Galmiche-Rolland L; Vabres P; Couloigner V; Audebert S; Misery L; Abasq-Thomas C
Pediatr Dermatol; 2020 Nov; 37(6):1128-1130. PubMed ID: 32770747
[TBL] [Abstract][Full Text] [Related]
10. Somatic PIK3CA mutations are present in multiple tissues of facial infiltrating lipomatosis.
Couto JA; Konczyk DJ; Vivero MP; Kozakewich HPW; Upton J; Fu X; Padwa BL; Mulliken JB; Warman ML; Greene AK
Pediatr Res; 2017 Nov; 82(5):850-854. PubMed ID: 28665924
[TBL] [Abstract][Full Text] [Related]
11. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
[TBL] [Abstract][Full Text] [Related]
12. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
Lindhurst MJ; Parker VE; Payne F; Sapp JC; Rudge S; Harris J; Witkowski AM; Zhang Q; Groeneveld MP; Scott CE; Daly A; Huson SM; Tosi LL; Cunningham ML; Darling TN; Geer J; Gucev Z; Sutton VR; Tziotzios C; Dixon AK; Helliwell T; O'Rahilly S; Savage DB; Wakelam MJ; Barroso I; Biesecker LG; Semple RK
Nat Genet; 2012 Jun; 44(8):928-33. PubMed ID: 22729222
[TBL] [Abstract][Full Text] [Related]
13. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
[TBL] [Abstract][Full Text] [Related]
15. Activating PIK3CA postzygotic mutations in segmental overgrowth of muscles with bone involvement in the body extremities.
Tian W; Sun L; Zhang Q; Zhao J; Guo Y; Zhong W; Liu L; Meirelles K; Tang S; Zhang J; Huang Y; Yin Y; Zhang N; Zhao Z; Li Q; Wu N; Fang P; Chang F; Wu Z
Mol Genet Genomics; 2022 Mar; 297(2):387-396. PubMed ID: 35122151
[TBL] [Abstract][Full Text] [Related]
16. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.
Kurek KC; Luks VL; Ayturk UM; Alomari AI; Fishman SJ; Spencer SA; Mulliken JB; Bowen ME; Yamamoto GL; Kozakewich HP; Warman ML
Am J Hum Genet; 2012 Jun; 90(6):1108-15. PubMed ID: 22658544
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
[TBL] [Abstract][Full Text] [Related]
18. Facial infiltrating lipomatosis with hemimegalencephaly and lymphatic malformations caused by nonhotspot phosphatidylinositol 3-kinase catalytic subunit alpha mutation.
Chen H; Sun B; Gao W; Jia H; Zhou L; Hua C; Lin X
Pediatr Dermatol; 2023; 40(6):1115-1119. PubMed ID: 37190882
[TBL] [Abstract][Full Text] [Related]
19. Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly.
Rios JJ; Paria N; Burns DK; Israel BA; Cornelia R; Wise CA; Ezaki M
Hum Mol Genet; 2013 Feb; 22(3):444-51. PubMed ID: 23100325
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
